Remarkably, 3 patients had SARS-CoV-2 infection after gene therapy (one after experimental gene therapy for WAS13, and two after approved gene therapy for ADA deficiency); all patients experienced a favorable clinical course. However, we did not observe substantial differences in terms of infection clearance (2 days spared) and symptom recovery (1 day spared) between treated and untreated patients ( I p i -value 0.86); nevertheless, we observed a faster mean time clearance in patients who had received at least 2 vaccination doses respect to the rest of our IEI cohort (17 versus 24 days). Keywords: antiviral drugs; COVID-19; inborn errors of immunity; monoclonal antibodies; primary immunodeficiencies; SARS-COV2; treatment EN antiviral drugs COVID-19 inborn errors of immunity monoclonal antibodies primary immunodeficiencies SARS-COV2 treatment 1 4 4 08/29/22 20220801 NES 220801 Many authors recently reported the effect of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic on patients affected by Inborn Errors of Immunity (IEI).1,2 Although mostly experiencing a mild disease and the course of the infection is comparable or even less symptomatic than the general population, young male IEIs patients were more severely affected and more frequently admitted to intensive care unit compared with the age-matched healthy peers.3 Most viral variants were actually first described in immunocompromised patients.4,5 Indeed, impaired B and/or T cell function can be responsible for persisting viral shedding often observed in IEI patients with subsequent higher risk of persistent viral replication and mutation within the host.6 Noteworthily, in the last 2 years Inborn Errors of type I IFN immunity and autoantibody-mediated phenocopies of IEIs were identified as responsible for life-threatening COVID-19. [Extracted from the article]